Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Analysis Of 27 Patients With Malignant Pleural Mesothelioma Treated At Our Institution

H. Kikuchi, H. Asahina, J. Sakakibara‐Konishi, N. Shinagawa, S. Oizumi, Y. Hida, K. Kaga, T. Inoue, N. Katoh, M. Nishimura
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
━━ Objective. We reviewed the clinical outcomes of patients with malignant pleural mesothelioma (MPM) treated at our institution. Methods. We conducted a retrospective analysis of 27 patients with MPM treated at our institution in the period from April 2005 to April 2013. Results. The patient characteristics were as follows: male female=26 1; age=35-76 years (median, 62); histology: epithelioid biphasic sarcomatoid=23 2 2; location, right left=14 13; clinical stage (IMIG) IA IB II III IV=3 5 4 9 6. The initial treatment was surgery chemotherapy best supportive care in 15 11 1 cases, including 14 patients treated with extrapleural pneumonectomy (EPP) and one patient treated with tumor resection. After EPP, three patients received adjuvant chemotherapy, five received hemithoracic radiotherapy (H-RT) and two received both. The median survival time (MST) of all patients was 21.8 months overall, compared to 30.7 months in the patients who received EPP. The patients who received H-RT after EPP demonstrated a significantly longer MST than those who did not (37.3 months vs. 12.0 months; p=0.04). Conclusions. The use of H-RT after EPP is associated with a better prognosis. (JJLC. 2015;55:2-8)
This paper references
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1002/AJIM.20246
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
Takehiko Murayama (2006)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1378/CHEST.123.2.551
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
10.1007/s00432-010-0834-7
Clinical investigation of malignant mesothelioma in Japan
N. Fujimoto (2010)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/j.athoracsur.2009.05.036
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)



Semantic Scholar Logo Some data provided by SemanticScholar